Sökning: WFRF:(Ibáñez Kristina) > (2016) > Introduction and Ut...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05768naa a2200913 4500 | |
001 | oai:DiVA.org:umu-124505 | |
003 | SwePub | |
008 | 160815s2016 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:133934247 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1245052 URI |
024 | 7 | a https://doi.org/10.3389/fphar.2016.001972 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1339342472 URI |
040 | a (SwePub)umud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a de Bruijn, Winnie4 aut |
245 | 1 0 | a Introduction and Utilization of High Priced HCV Medicines across Europe :b Implications for the Future |
264 | c 2016-07-22 | |
264 | 1 | b Frontiers Media SA,c 2016 |
338 | a electronic2 rdacarrier | |
520 | a Background: Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines to treat HCV infection grew 2.7% per year between 2004 and 2011, enhanced by the launch of the protease inhibitors (Hs) boceprevir (BCV) and telaprevir (TVR) in addition to ribavirin and pegylated interferon (pegIFN). Costs will continue to rise with new treatments including sofosbuvir, which now include interferon free regimens. Objective: Assess the uptake of BCV and TVR across Europe from a health authority perspective to offer future guidance on dealing with new high cost medicines. Methods: Cross-sectional descriptive study of medicines to treat HCV (pegIEN, ribavirin, BCV and TVR) among European countries from 2008 to 2013. Utilization measured in defined daily doses (DDDs)/1000 patients/quarter (DIOs) and expenditure in Euros/DDD. Health authority activities to influence treatments categorized using the 4E methodology (Education, Engineering, Economics and Enforcement). Results: Similar uptake of BCV and TVR among European countries and regions, ranging from 0.5 DIQ in Denmark, Netherlands and Slovenia to 1.5 DIQ in Tayside and Catalonia in 2013. However, different utilization of the new Pls vs. ribavirin indicates differences in dual vs. triple therapy, which is down to factors including physician preference and genotypes. Reimbursed prices for BCV and TVR were comparable across countries. Conclusion: There was reasonable consistency in the utilization of BCV and TVR among European countries in comparison with other high priced medicines. This may reflect the social demand to limit the transmission of HCV. However, the situation is changing with new curative medicines for HCV genotype 1 (GT1) with potentially an appreciable budget impact. These concerns have resulted in different prices across countries, with their impact on budgets and patient outcomes monitored in the future to provide additional guidance. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Hälsovetenskapx Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi0 (SwePub)303012 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Health Sciencesx Health Care Service and Management, Health Policy and Services and Health Economy0 (SwePub)303012 hsv//eng |
653 | a boceprevir | |
653 | a cross national drug utilization study | |
653 | a demand-side measures | |
653 | a Hepatitis C | |
653 | a introduction new medicines | |
653 | a sofosbuvir | |
653 | a telaprevir | |
700 | 1 | a Ibanez, Cristina4 aut |
700 | 1 | a Frisk, Pia4 aut |
700 | 1 | a Pedersen, Hanne Bak4 aut |
700 | 1 | a Alkan, Ali4 aut |
700 | 1 | a Bonanno, Patricia Vella4 aut |
700 | 1 | a Brkicic, Ljiljana S.4 aut |
700 | 1 | a Bucsicsa, Anna4 aut |
700 | 1 | a Dedet, Guillaume4 aut |
700 | 1 | a Eriksen, Jaranu Karolinska Institutet4 aut |
700 | 1 | a Fadare, Joseph O.4 aut |
700 | 1 | a Furst, Jurij4 aut |
700 | 1 | a Gallego, Gisselleu Umeå universitet,Klinisk neurovetenskap,School of Medicine, The University of Notre Dame Australia, Darlinghurst, NSW, Australia4 aut0 (Swepub:umu)giga0007 |
700 | 1 | a Godoi, Isabella P.4 aut |
700 | 1 | a Guerra Junior, Augusto A.4 aut |
700 | 1 | a Gursoz, Hakki4 aut |
700 | 1 | a Jan, Saira4 aut |
700 | 1 | a Jones, Jan4 aut |
700 | 1 | a Joppi, Roberta4 aut |
700 | 1 | a Kerman, Saim4 aut |
700 | 1 | a Laius, Ott4 aut |
700 | 1 | a Madzikwa, Newman4 aut |
700 | 1 | a Magnusson, Einar4 aut |
700 | 1 | a Maticic, Mojca4 aut |
700 | 1 | a Markovic-Pekovic, Vanda4 aut |
700 | 1 | a Massele, Amos4 aut |
700 | 1 | a Ogunleye, Olayinka4 aut |
700 | 1 | a O'Leary, Aisling4 aut |
700 | 1 | a Piessnegger, Jutta4 aut |
700 | 1 | a Sermet, Catherine4 aut |
700 | 1 | a Simoens, Steven4 aut |
700 | 1 | a Tiroyakgosi, Celda4 aut |
700 | 1 | a Truter, Ilse4 aut |
700 | 1 | a Thyberg, Magnus4 aut |
700 | 1 | a Tomekova, Kristina4 aut |
700 | 1 | a Wladysiuk, Magdalena4 aut |
700 | 1 | a Vandoros, Sotiris4 aut |
700 | 1 | a Vural, Elif H.4 aut |
700 | 1 | a Zara, Corinne4 aut |
700 | 1 | a Godman, Brianu Karolinska Institutet4 aut |
710 | 2 | a Karolinska Institutetb Klinisk neurovetenskap4 org |
773 | 0 | t Frontiers in Pharmacologyd : Frontiers Media SAg 7q 7x 1663-9812 |
856 | 4 | u https://doi.org/10.3389/fphar.2016.00197y Fulltext |
856 | 4 | u https://umu.diva-portal.org/smash/get/diva2:954252/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u https://www.frontiersin.org/articles/10.3389/fphar.2016.00197/pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-124505 |
856 | 4 8 | u https://doi.org/10.3389/fphar.2016.00197 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:133934247 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy